Research and Markets: Wyeth Has planned Four New Launches In 2007 And Secured Entry into the Japanese Rheumatoid Arthritis Market

Business Wire, July 26, 2006

DUBLIN, Ireland -- Wyeth is a global leader in pharmaceuticals, consumer healthcare and animal healthcare products. It has three primary businesses: Wyeth Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer Healthcare) and Fort Dodge Animal Health (Animal Health).

Pharmaceuticals segment includes branded human ethical pharmaceuticals, biologicals, vaccines and nutritionals. Consumer Healthcare products include analgesics, cough/cold/allergy remedies, nutritional supplements, and haemorrhoid, asthma and personal care items sold over-the-counter (OTC). Principal Animal Health products include vaccines, pharmaceuticals, parasite control and growth implants. The company sells its products to wholesalers, pharmacies, hospitals, physicians, retailers, and other healthcare institutions located in various markets in about 145 countries.

Wyeth has a strong competitive positioning in vaccines and biopharmaceutical segment. The company has also planned four new launches in 2007 and secured entry into the Japanese rheumatoid arthritis market, one of the most lucrative markets for this indication, for its drug Enbrel, through a majority-owned JV with Takeda.

Research and Markets (http://www.researchandmarkets.com/reports/c39925) has announced the addition of Wyeth: Company Analysis to their offering.

The global pharmaceutical industry is faced with the challenge of ensuring the viability of its high-cost, high-margin, blockbuster drugs-based business model. Wyeth, headquartered in New Jersey, has business interests in pharmaceuticals, consumer healthcare and animal healthcare products. The company has a diverse product portfolio and strong revenue-generating profitable brands.

The report starts with a historical overview of Wyeth and includes the company's organization structure and a description of its three business lines. The company has also been examined critically within the SWOT framework. A brief study of the global pharma industry landscape including the major players follows.

The report also includes a summary of Wyeth's financials and a peer group comparison-including GlaxoSmithKline, Novartis, and Merck-on some key indicators. The report concludes with an outlook on the company from two perspectives- the company itself and the analysts.

Products Mentioned:
Effexor
Protonix
Prevnar
Alliance revenue
Enbrel (outside of the US and Canada)
Nutrition
Premarin family
Zosyn/Tazocin

Countries Covered:
UK
US

Companies Mentioned:
Trubion Pharmaceuticals
Progenics Pharmaceuticals
Neurome

For more information visit http://www.researchandmarkets.com/reports/c39925